Charity Atkins

Publications by Year

Research Areas

Metabolism, Diabetes, and Cancer, Growth Hormone and Insulin-like Growth Factors, Cancer, Hypoxia, and Metabolism, Cancer-related gene regulation, Neuroblastoma Research and Treatments

Most-Cited Works

• → Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)(2012)608 cited
• → Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity(2013)426 cited
• → Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development(2013)226 cited
• → GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers(2009)98 cited
• → Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase(2009)79 cited
• → <i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor(2020)66 cited
• → Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity(2008)58 cited
• → In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate(2006)37 cited
• → Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)(2008)32 cited
• → Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase(2008)30 cited